Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism

International Archives of Allergy and Immunology

Volumn 136, Issue 2, 2005, Pages 165-172

  Fukushima, Chizu ^a   Matsuse, Hiroto ^a   Hishikawa, Yoshitaka ^a   Kondo, Yuki ^a   Machida, Ikuko ^a   Saeki, Sachiko ^a   Kawano, Tetsuya ^a   Tomari, Shinya ^a   Obase, Yasushi ^a   Shimoda, Terufumi ^a   Koji, Takehiko ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cytokines; Inflammation; Leukotriene receptor antagonist (pranlukast); Pranlukast

Indexed keywords

ALLERGEN; DEXAMETHASONE; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MESSENGER RNA; PEPTIDOLEUKOTRIENE; PRANLUKAST; CHROMONE DERIVATIVE;

ADULT; AGED; ALLERGY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; EOSINOPHIL; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; IN VITRO STUDY; LUNG PARENCHYMA; LYMPHOCYTE; MACROPHAGE; MALE; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SMOOTH MUSCLE FIBER; BIOSYNTHESIS; DRUG EFFECT; IMMUNOLOGY; LUNG; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CHROMONES; FEMALE; HUMANS; INTERLEUKIN-5; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; MIDDLE AGED; RECEPTORS, LEUKOTRIENE;

EID: 20144378092     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083325     Document Type: Article

References (28)

1. National Heart, Lung and Blood Institute: International Consensus Report on Diagnosis and Management of Asthma. Bethesda, National Institutes of Health, 1992.
2. National Heart, Lung and Blood Institute: Global Strategy for Asthma Management and Prevention Issued January, 1995. NIH Publication No. 02-3659. revised 2002. Bethesda, National Institutes of Health, 2002.
3. Obata T, Okada Y, Motoishi M, Nakagawa N, Terawaki T, Aishita H: In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol 1992;60:227-237.
4. Drazen JM: Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann N Y Acad Sci 1988;524:289-297.
5. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997;155:1235-1240.
6. Yamaguchi K, Tanifuji Y, Pan LH, Yoshida T, Sakurai S, Goto S, Kuroda S, Kobayashi H, Inoue H: Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. J Asthma 2001;38:51-57.
7. Diamant Z, Hitermann JT, van Rensen EL, Callenbach PM, Veselic-Charvat M, van der Veen H, Sont JK, Sterk PJ: The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-1253.
8. Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DW: Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: Modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996;154(4 Pt 1):850-857.
9. 2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma. Ann Allergy Asthma Immunol 1996;77:483-487.
10. Koji T, Brenner RM: Localization of estrogen receptor messenger ribonucleic acid in rhesus monkey uterus by nonradioactive in situ hybridization with digoxigenin-labeled oligodeoxynucleotides. Endocrinology 1993;132:382-392.
11. Adams JC: Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem 1981;29:775.
12. Yoshii A, Koji T, Ohsawa N, Nakane PK: In situ localization of ribosomal RNAs is a reliable reference for hybridizable RNA in tissue sections. J Histochem Cytochem 1995;43:321-328.
13. Tohda Y, Nakahara H, Kubo H, Haraguchi R, Fukuoka M, Nakajima S: Effect of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999;29:1532-1536.
14. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Willians DL Jr, Zeng Z, Liu O, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-30536.
15. Tomari S, Matsuse H, Machida I, Kondo Y, Kawano T, Obase Y, Fukushima C, Shimoda T, Kohno S: Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumor necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin Exp Allergy 2003;33:795-801.
16. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW: Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998;19:453-461.
17. Vargaftig BB, Singer M: Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003;28:410-419.
18. Singer M, Lefort J, Vargaftig BB: Granulocyte depletion and dexamethasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen. Am J Respir Cell Mol Biol 2002;26:74-84.
19. Vargaftig BB, Singer M: Leukotrienes, IL-13, and chemokines cooperate to induce BHR and mucus in allergic mouse lungs. Am J Physiol Lung Cell Mol Physiol 2003;284:L260-L269.
20. Vargaftig BB, Singer M: Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. Am J Physiol Lung Cell Mol Physiol 2003;285:L808-L818.
21. Ihaku D, Cameron L, Suzuki M, Molet S, Martin J, Hamid Q: Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. J Allergy Clin Immunol 1999;104:1147-1154.
22. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M: CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003;111:1032-1040.
23. Laviolette M, Malmström K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF: Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-1868.
24. Kawano T, Matsuse H, Kondo Y, Machida I, Saeki S, Tomari S, Mitsuta K, Obase Y, Fukushima C, Shimoda T, Kohno S: Cysteinyl leukotrienes induce nuclear factor kappa b activation and RANTES production in a murine model of asthma. J Allergy Clin Immunol 2003;112:369-374.
25. Bisgaard H: Role of leukotrienes in asthma pathophysiology. Pediatr Pulmonol 2000;30:166-176.
26. Lynch KR, O'Neill GP, Liu O, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF: Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789-793.
27. Mellor EA, Maekawa A, Austen KF, Boyce JA: Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001;98:7964-7969.
28. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, Liu Q, Clements M, Zeng Z, O'Neill GP, Jones TR, Lynch KR, Austin CP, Evans JF: Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001;163:226-233.